Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal.
Vrouchou
Panagiota
P
Kandaswamy
Prashanth
P
George
Elisabeth
E
Barnett
David
D
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics; D002945:Cisplatin / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D005971:Glutamates / Q000008:administration & dosage* / Q000191:economics; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics; D000068437:Pemetrexed; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D006113:United Kingdom
D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D002945:Cisplatin